Posted in Business News Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma Editor June 25, 2021 Please leave this field emptyGet every new post delivered right to your inbox. Email * Check your inbox or spam folder to confirm your subscription. Original Source
